Retatrutide FDA Approval Status 2026

Research-use supply note: Keep approval status separate from UAE research supply. Regulatory status and research supply are separate lanes. Retatrutide remains investigational as a medicine; Remy Peptides lists UAE retatrutide formats for in-vitro laboratory research only: 10mg pen, 20mg pen (99.841% HPLC), 30mg pen, 40mg pen, 10mg vial, and 40mg vial. For trust signals, see verified UAE researcher reviews; qualified lab or distributor inquiries can request wholesale pricing.

What Is Retatrutide’s FDA Approval Status in 2026?

As of June 4, 2026, retatrutide (LY-3437943) remains in Phase 3 without FDA approval, EMA approval, or clearance from any other major regulator. Lilly has not announced a New Drug Application filing with the FDA, and there is no approved pharmacy, prescription, or compounding pathway for retatrutide as a medicine. Today the molecule remains investigational and legally tied to clinical-trial settings rather than commercial prescribing.

The three public Phase 3 readouts so far are TRIUMPH-4 on December 11, 2025, TRANSCEND-T2D-1 on March 19, 2026, and the pivotal TRIUMPH-1 obesity trial on May 21, 2026. Those results strengthen the evidence base, but they do not change the current regulatory status: retatrutide remains in Phase 3 and still awaits any future filing package from Lilly. For the cross-drug status map, use the Approval Trackers hub.

Why Is Retatrutide Still in Phase 3?

FDA approval of any obesity medicine requires a completed registrational package, not a single standout result. Retatrutide’s Phase 3 development is still in the data-accumulation stage: three positive readouts are public, additional program results are still pending, and Lilly has not yet moved the molecule into a public NDA review cycle. Until those steps happen, approval remains a future possibility rather than a present status.

Lilly’s May 21, 2026 TRIUMPH-1 release added the pivotal obesity dataset that could anchor a future filing package, but it did not announce that an NDA had been submitted. TRIUMPH-2 (T2D) and TRIUMPH-3 (established CVD) readouts are still expected later in 2026. That is the practical Phase 3 signal right now: active late-stage development is continuing, and the approval clock cannot start until Lilly turns the broader dataset into a formal filing.

Has Eli Lilly Filed a Retatrutide NDA?

No. There is still no announced NDA filing for retatrutide. Some investor and media coverage discusses a possible 2026 submission window, but that is not the same as a filed NDA. The current NDA watch is therefore about milestones rather than calendar promises: TRIUMPH-2 and TRIUMPH-3 readouts later in 2026, clearer Lilly guidance on the sequence of indications, and a public statement that a submission has been made.

Retatrutide FDA Approval Date and Timeline

No retatrutide FDA approval date has been confirmed. The earliest credible timeline starts with an actual NDA submission, then FDA acceptance, then the assigned review clock and decision date. Until those steps are public, “retatrutide approval date,” “retatrutide FDA approval timeline,” and “when will retatrutide be FDA approved” queries all have the same answer: the status is still Phase 3, with no filed NDA and no PDUFA date.

For readers separating approval status from research-material format details: this page owns the regulatory question. Laboratory planning resources live separately, including retatrutide calculator, mg-to-click conversion tables, 30mg pen hardware details, and the Phase 3 trial schedule explainer. Those pages are research context, not human-use guidance.

Retatrutide Approval Status by Jurisdiction

Retatrutide is not approved by any major drug regulator. Eli Lilly has not filed a New Drug Application (NDA) or its equivalent in any jurisdiction as of June 4, 2026.

Updated 2026-06-04. Lilly’s most recent major retatrutide release (May 21, 2026) reported TRIUMPH-1 topline data but did not announce an NDA filing.

Retatrutide Regulatory & Trial Timeline

1. 2022 — Phase 1 first-in-human study (LY3437943) initiated by Eli Lilly.
2. June 2023 — Phase 2 results published in NEJM (Jastreboff et al.): 24.2% mean weight reduction at 48 weeks at the 12 mg dose.
3. 2024 — TRIUMPH Phase 3 program launched (TRIUMPH-1 through TRIUMPH-5).
4. December 11, 2025 — TRIUMPH-4 (knee osteoarthritis + obesity) topline readout.
5. March 19, 2026 — TRANSCEND-T2D-1 (type 2 diabetes) topline readout.
6. May 21, 2026 — TRIUMPH-1 (pivotal obesity) topline readout: 28.3% at 80 weeks on 12 mg, 30.3% at 104 weeks in the BMI ≥35 extension.
7. June 2026 — Full TRIUMPH-1 data presentation at the 86th ADA Scientific Sessions.
8. Expected later 2026 — TRIUMPH-2 (T2D) and TRIUMPH-3 (established CVD) readouts.
9. Future (TBD) — NDA filing with FDA. Lilly has not announced that a filing has been submitted.

Retatrutide Phase 3 Trial Results 2026

As of June 2026, three Phase 3 trials have reported positive topline results. TRIUMPH-1 (pivotal obesity) was announced May 21, 2026; it is the dataset most likely to anchor any future obesity filing package. TRIUMPH-4 (obesity + knee osteoarthritis) was announced December 11, 2025,^[1] and TRANSCEND-T2D-1 (type 2 diabetes) was announced March 19, 2026. TRIUMPH-2 (T2D) and TRIUMPH-3 (established CVD) readouts are expected later in 2026. Randomized trial designs may include placebo arms, and the broader safety and efficacy package is still being evaluated.

TRIUMPH-1: Pivotal Obesity Data (May 2026)

On May 21, 2026, Eli Lilly reported positive topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial. The randomized, double-blind, placebo-controlled study enrolled 2,339 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, excluding type 2 diabetes. Baseline mean BMI was 40.0 and baseline weight 112.7 kg. At 80 weeks, mean body-weight reduction was 19.0% at 4 mg (47.2 lb), 25.9% at 9 mg (64.4 lb), and 28.3% at 12 mg (70.3 lb) vs 2.2% on placebo. On the 12 mg arm, 45.3% of participants achieved ≥30% body-weight reduction and 65.3% reached a BMI under 30.

A prespecified blinded extension in completers with a baseline BMI ≥35, maintained on 12 mg to the maximum tolerated dose, showed continued reduction to 30.3% mean body-weight reduction (~85.0 lb) at 104 weeks without an apparent plateau. Cardiometabolic markers also shifted, including a 24.1 cm waist-circumference reduction and changes in non-HDL cholesterol, triglycerides, systolic blood pressure, and hs-CRP. Treatment discontinuation due to adverse events rose with dose: 4.1% on 4 mg, 6.9% on 9 mg, and 11.3% on 12 mg vs 4.9% on placebo. Dysesthesia was reported in up to 12.5% on 12 mg; urinary tract infections were also noted (rates not yet quantified publicly). Full data is scheduled for the 86th ADA Scientific Sessions in June 2026. Sources: Lilly investor release, TCTMD, AJMC.

TRIUMPH-4 Efficacy Data

The headline: 28.7% mean body-weight reduction at the 12 mg arm, one of the highest late-stage obesity-trial figures reported to date.^[1] Participants on 12 mg lost an average of 71.2 lbs (32.3 kg). The placebo group achieved approximately 2–3% body-weight reduction. As with other randomized trials, some participants may receive placebo rather than the investigational compound.

Beyond body weight, TRIUMPH-4 reported a WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain-score reduction of 4.5 points (75.8% improvement). That makes the study relevant to obesity plus knee osteoarthritis research, but it does not make retatrutide an approved osteoarthritis treatment.

TRANSCEND-T2D-1: Phase 3 Diabetes Data (March 2026)

On March 19, 2026, Eli Lilly announced positive topline results from TRANSCEND-T2D-1, the first Phase 3 trial evaluating retatrutide in type 2 diabetes. The 40-week, placebo-controlled study randomized 537 participants to retatrutide 4 mg, 9 mg, or 12 mg (starting at 2 mg with 4-week dose escalation). Retatrutide met all primary and key secondary endpoints: A1C reductions of 1.7% to 2.0% across arms (vs. 0.8% placebo), and body-weight reduction of 11.5% to 16.8% (12 mg = 36.6 lbs). GI adverse events were consistent with the incretin class: nausea (16.4–26.5%), diarrhea (18.7–26.3%), and vomiting (15.0–17.6%). Dysesthesia occurred in 2.3–4.5% of retatrutide-treated participants. Discontinuation rates due to adverse events were 2.2–5.1%. Detailed results will be presented at the American Diabetes Association Scientific Sessions in June 2026.

Remaining Readouts

With TRIUMPH-1 reported, the next public milestones on the late-stage map are TRIUMPH-2 (T2D) and TRIUMPH-3 (established CVD) readouts, expected later in 2026. TRIUMPH-6 (weight maintenance) extends into 2027. Retatrutide is also in Phase 3 for moderate-severe OSA, chronic low back pain, CV/renal outcomes, and MASLD/MASH, with cumulative TRIUMPH enrolment now exceeding 5,800. That broader sequence is the filing watch: more late-stage readouts, more clarity on the broader registrational package, and then any eventual NDA announcement. Track the moving timeline on our TRIUMPH trial tracker and compare it with the wider 2026 approval tracker.

TRIUMPH-4: Knee Osteoarthritis Outcomes

TRIUMPH-4 was the first Phase 3 obesity drug trial to specifically enroll participants with knee osteoarthritis. Its results are useful for understanding two research hypotheses: mechanical unloading from body-weight reduction and possible inflammatory-pathway changes. The study does not establish retatrutide as an approved knee osteoarthritis medicine.

Mechanical Unloading

Biomechanics literature often models knee loading as several kilograms of compressive force per kilogram of body weight during walking. In the TRIUMPH-4 context, a 28.7% mean body-weight reduction would be expected to reduce joint loading substantially. That mechanical model helps explain the WOMAC pain signal, but it does not prove cartilage preservation.

Anti-Inflammatory Effects

Independent of body-weight reduction, GLP-1 receptor agonists have demonstrated anti-inflammatory properties in preclinical studies. GLP-1 receptors are expressed in immune cells and synovial tissue, and GLP-1 pathway activation has been studied in relation to NF-kB signaling. The glucagon receptor component may also influence energy-expenditure and lipid-metabolism pathways. These mechanisms remain research context, not an approved clinical claim for retatrutide.

The approximately 8–9 percentage points of additional body-weight reduction with retatrutide versus tirzepatide in their respective knee OA trials is notable, though direct cross-trial comparisons are limited by differences in study design, populations, and endpoints. For ongoing TRIUMPH coverage, see the retatrutide Phase 3 trial tracker.

Limitations

Structural outcomes: A pain-score improvement does not necessarily mean cartilage preservation. Whether retatrutide-associated body-weight reduction slows radiographic progression of knee OA (joint space narrowing, osteophyte formation) is not addressed by the available data.

Durability: Knee OA symptom findings during active trial treatment may not persist after discontinuation. TRIUMPH-6 (weight maintenance) will provide relevant durability data.

Generalizability: TRIUMPH-4 enrolled participants with both obesity and knee OA. Whether the joint benefits extend to other weight-bearing joints (hip, ankle) or lower BMI ranges is unknown.

What About the Dysesthesia Safety Signal?

In TRIUMPH-1, dysesthesia — a skin sensitivity phenomenon described as tingling, tenderness, or altered sensation — was reported in up to 12.5% of participants on the 12 mg dose. That sits between TRIUMPH-4’s earlier high-dose signal and the lower single-digit incidence seen in TRANSCEND-T2D-1 (2.3–4.5%), and remains the most notable non-GI safety signal to emerge from the program. Urinary tract infections were also flagged in the TRIUMPH-1 topline release, though Lilly has not yet quantified the rates publicly.

Dysesthesia was generally described as mild to moderate in severity in public coverage. The rate distinguishes retatrutide from other GLP-1-class drugs, which do not typically report this signal at similar levels. Eli Lilly has stated that the signal is being monitored across ongoing TRIUMPH trials.

Whether dysesthesia and the new UTI observation affect regulatory review or labeling remains to be seen. The FDA will weigh both signals against the overall benefit-risk profile when the NDA is eventually submitted. Full TRIUMPH-1 safety tables are scheduled for the 86th ADA Scientific Sessions in June 2026.

For trial-arm GI rates, discontinuation data, and a full adverse-event breakdown, see our retatrutide safety guide.

Adverse Events in Retatrutide Trials

Across Phase 2 and Phase 3 clinical trials, the most frequently reported adverse events with retatrutide have been gastrointestinal in nature. Nausea, diarrhea, vomiting, and constipation were the leading symptoms, consistent with the tolerability profile of GLP-1 drugs and other incretin-based medications. These adverse events generally clustered during the trial escalation window and diminished over time in the published trial context.

Retatrutide’s mechanism of action under investigation includes delayed gastric emptying and appetite-pathway effects, which are part of the body-weight findings reported in trials. At the 12 mg arm in TRIUMPH-4, nausea and vomiting rates were broadly comparable to rates seen with other incretin-based obesity trials. Cross-drug comparisons remain limited by differences in populations, duration, dose-escalation designs, and endpoint definitions. The FDA will evaluate the full safety package only after any future NDA submission.

It is important to note that retatrutide is not eligible for ordinary compounded-drug marketing as an approved ingredient. In a September 2025 warning letter, FDA said there were no FDA-approved applications on file for the cited compounded retatrutide products and described them as unapproved new drugs.^[4] Full tolerability data by trial arm is available in our retatrutide safety guide.

When Could Retatrutide Be Approved?

No approval date has been confirmed. Based on publicly available information, the sequence still looks like this:

2026: more late-stage data. Three Phase 3 readouts are already public: TRIUMPH-4 (Dec 2025), TRANSCEND-T2D-1 (Mar 2026), and the pivotal TRIUMPH-1 obesity trial (May 21, 2026). TRIUMPH-2 (T2D) and TRIUMPH-3 (established CVD) readouts are expected later in 2026. Full TRIUMPH-1 data lands at the 86th ADA Scientific Sessions in June 2026. Lilly still needs the broader late-stage package before filing.

Next milestone: future NDA filing. Lilly still needs a broader late-stage package before filing, and as of June 4, 2026 the company has not publicly announced that an NDA has been filed.

After filing: FDA review and decision. Only once Lilly submits an NDA can a credible approval window be estimated. Standard review timelines matter, but they start from an actual filing date rather than investor-side projections. Track all upcoming decisions on the obesity drug approval tracker.

Can You Get a Retatrutide Prescription?

No. Because retatrutide is not an approved drug, it cannot be prescribed or dispensed by a retail pharmacy. There is no prescription pathway, no off-label prescribing option, and no legitimate online pharmacy pathway for retatrutide as a medicine. Human clinical access is limited to authorized clinical trials. Keep the distinction clear: research-only supply is not the same as a regulatory approval, prescription, or clinical-use pathway.

Concerns About Illegal Sales

The FDA has issued warning letters involving the sale of retatrutide and other GLP-1 products online. The September 2025 warning letter cited on this page stated that the seller’s compounded retatrutide products had no approved applications on file and were not eligible for certain compounding exemptions.^[4] For a country-by-country breakdown of what is and isn’t permitted, see our peptide legality guide. Unlike approved alternatives such as semaglutide or tirzepatide, retatrutide has no approved pharmaceutical supply chain outside Eli Lilly’s controlled trial environment.

How to Find Retatrutide Clinical Trials

Retatrutide studies can be searched on ClinicalTrials.gov, which is a government-run website listing human clinical trials for investigational medications like retatrutide. Use the search term “retatrutide” or “LY-3437943.” Enrollment status varies by study and site, and several late-stage programs continue beyond 2026. ClinicalTrials.gov listings should be read with study staff and qualified healthcare professionals before any enrollment decision.

What Is Retatrutide?

Retatrutide (LY-3437943) is an investigational once-weekly injectable drug developed by Eli Lilly that simultaneously activates three gut hormone pathways: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. It is the first drug targeting all three of these pathways to reach Phase 3 obesity clinical trials. For a detailed breakdown of each receptor’s contribution, see our triple-agonist pathway analysis.

How Retatrutide Differs from Approved Obesity Medications

The three-hormone mechanism is the key differentiator. Currently approved medications for weight management include semaglutide (Wegovy) and tirzepatide (Zepbound), which target one or two of these hormone pathways. Retatrutide adds glucagon receptor activation on top of the GLP-1 and GIP pathways used by tirzepatide. In trial populations, that triple-agonist design has been associated with larger mean body-weight reductions than earlier single- or dual-agonist trial benchmarks, though cross-trial comparisons have limits. For a head-to-head comparison with these alternatives, see Retatrutide vs Tirzepatide vs CagriSema. Several other pharmaceutical companies are also developing multi-receptor obesity medicines, including Novo Nordisk’s amylin-based petrelintide and zenagamtide, as well as CagriSema.

In the Phase 2 trial published in the New England Journal of Medicine in 2023, the 12 mg arm produced 24.2% mean body-weight reduction at 48 weeks. The Phase 3 readouts extended that signal: TRIUMPH-4 reported 28.7% in obesity plus knee osteoarthritis (Dec 2025), and the pivotal TRIUMPH-1 trial reported 28.3% mean body-weight reduction at 80 weeks on 12 mg (up to 30.3% at 104 weeks in the BMI ≥35 extension) on May 21, 2026. For trial-schedule context, see our retatrutide dosage guide. For laboratory-format lookup, use the retatrutide clicks guide. For ongoing study coverage, use the TRIUMPH trial tracker and the 2026 approval tracker.